FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1744-1746 April 20, 2006 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Antiplatelet therapy with aspirin, an irreversible inhibitor of platelet cyclooxygenase, has earned its rightful place as a cornerstone of treatment for reducing cardiovascular events in patients with established vascular disease.^1,2 This statement is based on consistent results favoring aspirin in a large number of randomized, controlled trials in populations with either acute or long-term disease. Clopidogrel, by inhibiting the adenosine diphosphate P2Y₁₂ receptor, offers a distinctly different mechanism to reduce platelet activation and aggregation. As monotherapy, clopidogrel has been shown to be effective in reducing the risk of vascular events in patients with established vascular disease.³

Even more important, when . . . [Full Text of this Article]

Source Information

From Brigham and Women's Hospital and Harvard Medical School (M.A.P.) and the Journal (J.A.J.) — all in Boston.

This article was published at www.nejm.org on March 12, 2006.

This article has been cited by other articles:

• Cacoub, P. P., Bhatt, D. L., Steg, P.G., Topol, E. J., Creager, M. A., for the CHARISMA Investigators, (2009). Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J 0: ehn534v1-10 [Abstract] [Full Text]  
• Goldstein, L. B. (2008). Response to Letter by Mascitelli et al. Stroke 39: e181-e181 [Full Text]  
• Inoue, Y., Kobayashi, T., Morikawa, A., Taddio, A., Rose, C. D., Greil, G. F., Manning, W. J., Newburger, J. W., Sleeper, L. A., Burns, J. C. (2007). Treatment of Kawasaki Disease. NEJM 356: 2746-2748 [Full Text]  
• (2006). Dual Antiplatelet Therapy Tested in High-Risk Stable Patients. Journal Watch Cardiology 2006: 2-2 [Full Text]  
• Gorelick, P., Sechenova, O., Hennekens, C. H. (2006). Evolving Perspectives on Clopidogrel in the Treatment of Ischemic Stroke. J CARDIOVASC PHARMACOL THER 11: 245-248 [Abstract]  
• Jhund, P., McMurray, J. J.V. (2006). Does Aspirin Reduce the Benefit of an Angiotensin-Converting Enzyme Inhibitor?: Choosing Between the Scylla of Observational Studies and the Charybdis of Subgroup Analysis. Circulation 113: 2566-2568 [Full Text]  
• Goldfarb, B. (2006). Clopidogrel Adds No Benefit to Aspirin in High-Risk Patients. DOC News 3: 1-11 [Full Text]  
• (2006). Dual Antiplatelet Therapy Tested in High-Risk Stable Patients. Journal Watch Cardiology 2006: 1-1 [Full Text]